The Resting-state EEG Gamma Oscillations in Alzheimer's Disease

Sponsor

Görsev Yener, MD, PhD (Other)

Overall Status

Completed

CT.gov ID

NCT05989087

Collaborator

(none)

Enrollment

Location

76.9

Actual Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to investigate resting-state gamma activity changes in CSF-proven early-onset Alzheimer's disease (EOAD) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.

Condition or Disease	Intervention/Treatment	Phase
Alzheimer Disease, Early Onset	Diagnostic Test: CSF

Detailed Description

This cross-sectional study included 24 drug-naive CSF-proven EOAD patients and age-, sex, and education-matched healthy controls. All participants underwent a detailed neuropsychological evaluation, resting-state EEG recording, and MRI. Gamma power and coherence were measured in total gamma (30-48 Hz), gamma-1 (30-35 Hz), gamma-2 (35-40 Hz), and gamma-3 (40-48 Hz) frequency bands. Gray matter volumes were extracted for 54 ROIs and compared between groups. Discriminant analysis was performed to determine the classification accuracy of gamma activity for EOAD. Finally, correlations between CSF, neuropsychological tests, EEG, and MRI measures were explored.

Study Design

Study Type:

Observational

Actual Enrollment :

51 participants

Observational Model:

Other

Time Perspective:

Retrospective

Official Title:

The Underestimated Utility of Resting-state Gamma Oscillations: Both Increase and Decrease of Gamma Discriminates Early-onset Alzheimer's Disease Patients From Healthy Individuals

Actual Study Start Date :

Nov 7, 2012

Actual Primary Completion Date :

Jan 2, 2016

Actual Study Completion Date :

Apr 5, 2019

Arms and Interventions

Arm	Intervention/Treatment
Early-onset Alzhimer's disease Patients were recruited from the outpatient memory clinics of the Department of Neurology, Dokuz Eylül University Hospital. The patient group was diagnosed by an expert neurologist, according to the National Institute on Aging-Alzheimer's Association diagnostic criteria for Alzheimer's disease	Diagnostic Test: CSF Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests. Other Names: MRI Neuropsychological tests
Healthy controls Age-and gender-matched healthy volunteers were recruited via advertisements and word-of-mouth.

Arm

Intervention/Treatment

Early-onset Alzhimer's disease

Patients were recruited from the outpatient memory clinics of the Department of Neurology, Dokuz Eylül University Hospital. The patient group was diagnosed by an expert neurologist, according to the National Institute on Aging-Alzheimer's Association diagnostic criteria for Alzheimer's disease

Diagnostic Test: CSF

Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.

Other Names:

MRI

Neuropsychological tests

Healthy controls

Age-and gender-matched healthy volunteers were recruited via advertisements and word-of-mouth.

Outcome Measures

Primary Outcome Measures

EEG [Day 2]
The resting state EEG recordings were acquired using Easy-Cap comprising 30 Ag/AgCl electrodes placed according to the international 10-20 system. Coherence and maximum peak power of the total gamma (30-48 Hz) and sub-gamma bands [gamma-1 (30-35 Hz), gamma-2 (35-40 Hz), and gamma-3 (40-48 Hz)] were measured for each participant.

Secondary Outcome Measures

Correlation Analysis [3 months]
Correlations between CSF, NPT, EEG, and MRI measures were investigated.
Discriminant Analysis [3 months]
The discriminative power of gamma measures (power and coherence) was investigated with discriminant analysis (DA).
MRI [Day 1]
Participants underwent structural magnetic resonance imaging on a Philips Achieva 1.5 Tesla scanner. The gray matter volumes and cortical thickness were obtained from the 3D-T1 weighted TFE sequence (TR: 9ms, TE: 4ms, FOV: 240mm, matrix: 256, slice thickness: 1mm, NSA: 1).

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

For all participants: Age < 65
For EOAD patients: Meeting National Institute on Aging-Alzheimer's Association diagnostic criteria.
For healthy controls: MMSE>25 IADL = 8

Exclusion Criteria:

For EOAD patients: MMSE > 24 GDS > 14 Having treatment with antipsychotics and comorbidities that may affect cognitive abilities.
For healthy controls: Having neurological and/or cognitive abnormalities Having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. GDS > 14
For all participants: Having neurological (other than AD) or any other serious disease (cancer, systemic disease)